Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

ClinicalTrials.gov ID: NCT01978093

Public ClinicalTrials.gov record NCT01978093. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 20, 2026, 12:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine 792014 Compared to Merck & Co, Inc. Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) Vaccine in Healthy Infants and Toddlers

Study identification

NCT ID
NCT01978093
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
600 participants

Conditions and interventions

Interventions

  • Hib-MenCY-TT (MenHibrix®) Biological
  • Pediarix® Biological
  • Rotarix® Biological
  • Prevnar 13® Biological
  • PedvaxHIB® Biological
  • Havrix® Biological

Biological

Eligibility (public fields only)

Age range
6 Weeks to 12 Weeks
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2014
Primary completion
Mar 17, 2016
Completion
Mar 17, 2016
Last update posted
Sep 13, 2018

2014 – 2016

United States locations

U.S. sites
26
U.S. states
10
U.S. cities
26
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35205
GSK Investigational Site Fayetteville Arkansas 72703
GSK Investigational Site Jonesboro Arkansas 72401
GSK Investigational Site Fresno California 93726
GSK Investigational Site Huntington Beach California 92648
GSK Investigational Site Paramount California 90723
GSK Investigational Site Pleasanton California 94588
GSK Investigational Site Roseville California 95661
GSK Investigational Site Sacramento California 95823
GSK Investigational Site San Jose California 95119
GSK Investigational Site Santa Clara California 95051
GSK Investigational Site Walnut Creek California 94596
GSK Investigational Site Fall River Massachusetts 02721
GSK Investigational Site Woburn Massachusetts 01801
GSK Investigational Site Niles Michigan 49120
GSK Investigational Site Stevensville Michigan 49127
GSK Investigational Site Raleigh North Carolina 27609
GSK Investigational Site Cleveland Ohio 44121
GSK Investigational Site Dayton Ohio 45406
GSK Investigational Site Hermitage Pennsylvania 16148
GSK Investigational Site Charleston South Carolina 29406
GSK Investigational Site Layton Utah 84041
GSK Investigational Site Murray Utah 84124
GSK Investigational Site Orem Utah 84057
GSK Investigational Site Roy Utah 84067
GSK Investigational Site Syracuse Utah 84075

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01978093, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 13, 2018 · Synced Jul 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01978093 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →